Citations

Mayo Clinic

Showing 10 of 108602 citations.

Arthroscopic Airbrush-Assisted Cell Spraying for Cartilage Repair: Design, Development, and Characterization of Custom-Made Arthroscopic Spray Nozzles
Dijkstra, Koen, Hendriks, Jan , Karperien, Marcel , Vonk, Luciënne A. , Saris, Daniël B.F. , Vonk, Lucienne A

Tissue Engineering Part C: Methods | July 6, 2017 | Volume: 23 | Issue: 9 | Pages: 505-515

10.1089/ten.tec.2017.0228 | PMID 28683651 Get It

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
Paludo, Jonas , LaPlant, Betsy, Halvorson, Alese E. , Kumar, Shaji , Hayman, Suzanne R. , Lust, John A., Kapoor, Prashant , Russell, Stephen J. , Dingli, David , Lin, Yi , Bergsagel, P. Leif , Sher, Taimur , Chanan‐Khan, Asher , Stewart, A. Keith, Reeder, Craig B. , Richardson, Paul G. , Lacy, Martha Q. , Bergsagel, P. Leif , Mikhael, Joseph R., LaPlant, Betsy R, Buadi, Francis K. , Chanan-Khan, Asher A., Mıkhael, Joseph , Gertz, Morie A. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I. , Fonseca, Rafaël , Roy, Vivek , Ailawadhi, Sikander , Richardson, Paul Gerard Guy , Rajkumar, S. Vincent , Paludo, Jonas , Russell, Stephen J , Dingli, David , Lin, Yi

Blood | July 6, 2017 | Volume: 130 | Issue: 10 | Pages: 1198-1204

10.1182/blood-2017-05-782961 | PMID 28684537 Get It

Key Points PVD is an active combination in relapsed lenalidomide-refractory MM patients. PVD with weekly bortezomib offers a simpler, more convenient, and well-tolerated regimen option.
NTRK1-3 point mutations in poor prognosis thyroid cancers.
Iñiguez‐Ariza, Nicole M. , Bible, Keith C. , Shridhar, Vijayalakshmi, Smallridge, Robert C., Menefee, Michael E., Hilger, Crystal, Severson, Eric A. , Morris, John C., Chintakuntlawar, Ashish V. , Ryder, Mabel

Journal of Clinical Oncology | July 6, 2017 | Volume: 35 | Issue: 15_suppl | Pages: 6087-6087

10.1200/jco.2017.35.15_suppl.6087 Get It

6087 Background: NTRK1-3 fusions, identified in pediatric radiation-associated thyroid cancers, are low frequency oncogenic drivers that can trigger constitutive activation of TrK1-3 tyrosine kinase domains with responsively heightened downstream signaling through RAS-MAPK, PI3K-AKT, and/or PLCγ-PKC. NTRK point mutations are rare and of largely uninvestigated oncogenic potential, but some appear oncogenic. Methods: Advanced thyroid cancer (TC) patients (pts) requiring systemic therapy at Mayo Clinic sites underwent tumor genetic interrogation using Foundation One analyses with the goal of informing salvage therapeutic strategies. In this IRB-approved study, data from pts with TCs bearing NTRK point mutations were retrospectively analyzed, as this occurrence was unexpected but potentially of prognostic and/or therapeutic relevance. Results: Five of 55 pts (9%) with advanced TCs subject to Foundation One tumor interrogation had NTRK1-3 point mutations (allele frequency, AF, 15-49%); none had fusions. All 5 tumors had microsatellite stability; 4/5 had low tumor mutation burden (2-5 mutations/megabase). NTRK mutations in 3 anaplastic TC (ATC) pts (15% prevalence) were: NTRK3 I749M (AF 15%; overall survival, OS, 15 mos), NTRK1 R744H (AF not available; OS 9.5 mos), and NTRK1 R583H (AF 20.1%; OS > 4.9 mos); NTRK2 S167Y (AF 49%; OS > 51 mos) or NTRK1 R6W (AF 42%; OS > 60 mos) were found in one papillary (PTC) and one Hürthle cell (HCC) TC pt respectively (summary table below). Conclusions: NTRK point mutations, but not fusions, were unexpectedly identified in 9% of assessed advanced TCs - but remarkably in 15% of ATCs. Mutated NTRKs, along with oncogenic p53 and TERT, may contribute to TC progression, especially in ATC, consequent to downstream activation of MAPK and PI3K-AKT pathways. We posit that NTRK point mutations may have therapeutic implications for treatment of refractory disease. [Table: see text]
Tumor mutational burden (TMB) and co-existing actionable mutations in biliary tract cancers (BTC).
Jain, Apurva , Shroff, Rachna T. , Zuo, Mingxin, Weatherly, J., Isaacs, Randi , Ali, Siraj M. , Javle, Milind , Meric‐Bernstam, Funda , Bekaii‐Saab, Tanios

Journal of Clinical Oncology | July 6, 2017 | Volume: 35 | Issue: 15_suppl | Pages: 4086-4086

10.1200/jco.2017.35.15_suppl.4086 Get It

4086 Background: Mutations in DNA repair pathway were identified in 13% of Biliary Tract Cancers (BTC) [ Cancer2016;122:3838–3847]. High TMB tumors including melanoma, lung cancer and those with microsatellite instability (MSI-H) are associated with susceptibility to immune blockade using checkpoint inhibitors. TMB data in BTC is limited and its association with actionable somatic mutation (mut) profiles in BTC is unknown. Methods: Comprehensive genomic profiling (CGP) of 309 FFPE tissue blocks of BTC pts with a hybrid capture of all coding exons of 236 cancer-related genes and 47 introns of 19 genes rearranged in cancer was done using FoundationOne. Base substitutions, indels, gene fusion/rearrangements, TMB, and MSI status were assessed. TMB was calculated by counting mutations across a 1.25Mb region and classified into high (TMBH; ≥20 mut/Mb), intermediate (TMBI; 6 - 19mut/Mb) and low (TMBL; < 6mut/Mb). MSI high (MSIH) and Stable (MSS) status was assigned by a computational algorithm examining 114 intronic homopolymer loci. Patients with TMB ≥6 mut/Mb (N = 60) were included in the clinical correlative portion of this study. Results: Sixty patients with TMB ≥6 mut were identified out of 309 pts of which 9 (15%) were TMBH and 51 (85%) were TMBI. These included 3 (5%) MSIH and 18 (30 %) MSS. The median age was 59 years (range: 29-86), 35 (58%) were females, majority were intrahepatic cholangiocarcinoma (n = 31; 52%) and 28 (47%) presented with advanced disease at diagnosis. Twenty three (38%) pts had received radiation therapy, 28 (47%) surgery and 3 (5%) received immunotherapy. Most frequent co-existing mut seen was TP53 (N = 35; 58%). APC mut was seen in 7 (12%) pts. DNA repair pathway muts ( MSH6, BRCA1, BRCA2, ATM, MLH1, or MSH2 genes) were identified in 78% of TMBH versus 16% in TMBI cases (p < 0.0001). Frequency of PIK3CA mut differed significantly between TMBH and TMBI (44% vs 10%, p < 0.0001). Pts with TMBI had a significantly better median OS (110 weeks) as compared to TMBH (43 weeks) (p = 0.003). Conclusions: DNA repair pathway and PIK3CA mut maybe associated with TMBH in BTC. A better understanding of TMB and associated actionable mutations in BTC may be of value for the management of BTC patients with targeted agents and immunotherapy.
Precision medicine for gallbladder cancer using somatic copy number amplifications (SCNA) and DNA repair pathway gene alterations.
Javle, Milind , Catenacci, Daniel V.T. , Jain, Apurva , Young, Lauren , Wang, Kai , Chung, Jon , Schrock, Alexa B. , Gay, Laurie M. , Ahn, Daniel H. , Kelley, Robin Kate , Ganesan, Shridar , Stephens, Phil , Miller, Vincent A. , Ali, Siraj M. , Shroff, Rachna T. , Hezel, Aram F. , Goyal, Lipika , Bekaii‐Saab, Tanios , Ross, Jeffrey S

Journal of Clinical Oncology | July 6, 2017 | Volume: 35 | Issue: 15_suppl | Pages: 4076-4076

10.1200/jco.2017.35.15_suppl.4076 Get It

4076 Background: Gallbladder carcinoma (GBC) is commonly diagnosed at an advanced, unresectable disease stage and has a poor prognosis. Comprehensive genomic profiling (CGP) has a developing role in guiding systemic, precision anti-cancer therapy. Methods: We performed hybrid capture-based CGP on FFPE samples for 491 consecutive advanced GBCs. Mean coverage depth was >550X for up to 315 cancer-related genes plus 37 introns from 28 genes frequently rearranged in cancer. All 4 classes of genomic alterations (GA) were detected. Tumor mutational burden (TMB) was determined on up to 1.1 Mb of sequenced DNA. Results: Median age was 64 (range 25-88) and 69% (337/491) of patients were female. 96% (470), 2.9% (14), and 1.4% (7) of GBC patients had the diagnosis of adenocarcinoma, adenosquamous, or carcinoma not specified (NOS), respectively. Commonly altered genes were TP53 (62%), CDNK2A (31%), ARID1A (18%), and SMAD4 (15%), and most of the genetic aberrations (GA) were short variants. Potentially targetable SCNAs (including ERBB genes, MET, FGFRs, and the CCND1-FGF3/4/19 11q13 amplicon) were identified in 21% of cases (Table). Oncogenic BRAF, ALK, or FGFR2/3 rearrangements were found in 7 cases (1.4%). Moreover, 7.8% of cases had BRCA2 or ATM GA, and 0.8% had INI1loss suggesting benefit from PARP or EZH2 inhibitors, respectively. TMB was low; the 25th, 50th, and 75th percentiles were 2.5, 3.8 and 6.3 mutations/Mb, respectively. Less than 1% of cases had microsatellite instability. Radiological response to TKIs and immunotherapy was noted. Conclusions: In addition to the significant opportunity for anti-HER targeted therapies, other subsets of GBC cases harbored kinase GA (particularly SCNA), the 11q13 amplicon, or BRCA2/ ATM/ INI1mutations that are linked to therapeutic benefit. How the frequency of both driver SCNA and DNA repair alterations in GBC can be linked with inflammation awaits additional investigation. [Table: see text]
A Teenage Girl With Aseptic Meningitis and Unilateral Blurry Vision
Starr, Matthew R. , Smith, Wendy M. , Starr, Matthew R

JAMA Ophthalmology | July 6, 2017 | Volume: 135 | Issue: 10 | Pages: 1111

10.1001/jamaophthalmol.2017.0747 | PMID 28687842 Get It

CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide
Moutal, Aubin , Yang, Xiaofang , Li, Wennan , Gilbraith, Kerry B., Luo, Shizhen , Cai, Song , François‐Moutal, Liberty , Chew, Lindsey A. , Yeon, Seul Ki , Bellampalli, Shreya S. , Qu, Chaoling, Xie, Jennifer Y. , Ibrahim, Mohab , Khanna, May , Porreca, Frank , Khanna, Rajesh , Park, Ki Duk , Khanna, Rajesh , Chew, Lindsey A

Pain | July 6, 2017 | Volume: 158 | Issue: 12 | Pages: 2301-2319

10.1097/j.pain.0000000000001002 | PMID 28809766 Get It

Abstract Neurofibromatosis type 1 (NF1) is a rare autosomal dominant disease linked to mutations of the Nf1 gene. Patients with NF1 commonly experience severe pain. Studies on mice with Nf1 haploinsufficiency have been instructive in identifying sensitization of ion channels as a possible cause underlying the heightened pain suffered by patients with NF1. However, behavioral assessments of Nf1 +/− mice have led to uncertain conclusions about the potential causal role of Nf1 in pain. We used the clustered regularly interspaced short palindromic repeats (CRISPR)-associated 9 (CRISPR/Cas9) genome editing system to create and mechanistically characterize a novel rat model of NF1-related pain. Targeted intrathecal delivery of guide RNA/Cas9 nuclease plasmid in combination with a cationic polymer was used to generate allele-specific C-terminal truncation of neurofibromin, the protein encoded by the Nf1 gene. Rats with truncation of neurofibromin, showed increases in voltage-gated calcium (specifically N-type or CaV2.2) and voltage-gated sodium (particularly tetrodotoxin-sensitive) currents in dorsal root ganglion neurons. These gains-of-function resulted in increased nociceptor excitability and behavioral hyperalgesia. The cytosolic regulatory protein collapsin response mediator protein 2 (CRMP2) regulates activity of these channels, and also binds to the targeted C-terminus of neurofibromin in a tripartite complex, suggesting a possible mechanism underlying NF1 pain. Prevention of CRMP2 phosphorylation with ( S )-lacosamide resulted in normalization of channel current densities, excitability, as well as of hyperalgesia following CRISPR/Cas9 truncation of neurofibromin. These studies reveal the protein partners that drive NF1 pain and suggest that CRMP2 is a key target for therapeutic intervention.
Accuracy of Resting Metabolic Rate Prediction Equations in Athletes
Jagim, Andrew R. , Camic, Clayton L., Kisiolek, Jacob N. , Luedke, Joel, Erickson, Jacob L. , Jones, Margaret T. , Oliver, Jonathan M. , Erickson, Jacob, Jagim, Andrew R

Journal of Strength and Conditioning Research | July 6, 2017 | Volume: 32 | Issue: 7 | Pages: 1875-1881

10.1519/jsc.0000000000002111 | PMID 28682934 Get It

Abstract Jagim, AR, Camic, CL, Kisiolek, J, Luedke, J, Erickson, J, Jones, MT, and Oliver, JM. Accuracy of resting metabolic rate prediction equations in athletes. J Strength Cond Res 32(7): 1875–1881, 2018—The purpose of this study was to determine the accuracy of 5 different resting metabolic rate (RMR) prediction equations in male and female athletes. Twenty-two female (19.7 ± 1.4 years; 166.2 ± 5.5 cm; 63.5 ± 7.3 kg; 49.2 ± 4.3 kg of fat-free mass (FFM); 23.4 ± 4.4 body fat (BF) percent) and 28 male (20.2 ± 1.6 years; 181.9 ± 6.1 cm; 94.5 ± 16.2 kg; 79.1 ± 7.2 kg of FFM; 15.1 ± 8.5% BF) athletes were recruited to participate in 1 day of metabolic testing. Assessments comprised RMR measurements using indirect calorimetry, and body composition analyses using air displacement plethysmography. One-way repeated-measures analysis of variance with follow-up paired t tests were selected to determine differences between indirect calorimetry and 5 RMR prediction equations. Linear regression analysis was used to assess the accuracy of each RMR prediction method. An alpha level of p ≤ 0.05 was used to determine statistical significance. All the prediction equations significantly underestimated RMR while the Cunningham equation had the smallest mean difference (−165 kcals). In men, the Harris-Benedict equation was found to be the best prediction formula with the lowest root-mean-square prediction error value of 284 kcals. In women, the Cunningham equation was found to be the best prediction equation with the lowest root-mean-squared error value of 110 kcals. Resting metabolic rate prediction equations consistently seem to underestimate RMR in male and female athletes. The Harris-Benedict equation seems to be most accurate for male athletes, whereas the Cunningham equation may be better suited for female athletes.
Targeting MYC as a Therapeutic Intervention for Anaplastic Thyroid Cancer
Enomoto, Keisuke , Zhu, Xuguang , Park, Sun‐Mi , Zhao, Li , Qi, Jun , Copland, John A. , Cheng, Sheue-yann, Zhu, Yuelin Jack , Willingham, Mark C. , Meltzer, Paul S. , Cheng, Sheue-yann

The Journal of Clinical Endocrinology & Metabolism | July 6, 2017 | Volume: 102 | Issue: 7 | Pages: 2268-2280

10.1210/jc.2016-3771 | PMID 28368473 Get It

Abstract Context: Recent studies showed that transcription of the MYC gene is driven by the interaction of bromodomain and extraterminal domain (BET) proteins with acetylated histones on chromatin. JQ1, a potent inhibitor that effectively disrupts the interaction of BET proteins with acetylated histones, preferentially suppresses transcription of the MYC gene. We recently reported that JQ1 decreased thyroid tumor growth and improved survival in a mouse model of anaplastic thyroid cancer (ATC) by targeting MYC transcription. The role of MYC in human ATC and whether JQ1 can effectively target MYC as a treatment modality have not been elucidated. Objective: To understand the underlying molecular mechanisms of JQ1, we evaluated its efficacy in human ATC cell lines and xenograft models. Design: We determined the effects of JQ1 on proliferation and invasion in cell lines and xenograft tumors. We identified key regulators critical for JQ1-affected proliferation and invasion of tumor cells. Results: JQ1 markedly inhibited proliferation of four ATC cell lines by suppression of MYC and elevation of p21and p27 to decrease phosphorylated Rb and delay cell cycle progression from the G0/G1 phase to the S phase. JQ1 blocked cell invasion by attenuating epithelial-mesenchymal transition signals. These cell-based studies were further confirmed in xenograft studies in which the size and rate of tumor growth were inhibited by JQ1 via inhibition of p21-cyclin/cyclin-dependent kinase-Rb-E2F signaling. Conclusions: These results suggest targeting of the MYC protein could be a potential treatment modality for human ATC for which effective treatment options are limited.
Mixed integer programming with dose‐volume constraints in intensity‐modulated proton therapy
Zhang, Pengfei , Fan, Neng , Shan, Jie , Bues, Martin , Schild, Steven E. , Liu, Wei , Bues, Martin

Journal of Applied Clinical Medical Physics | July 6, 2017 | Volume: 18 | Issue: 5 | Pages: 29-35

10.1002/acm2.12130 | PMID 28681976 Get It

AbstractBackgroundIn treatment planning for intensity‐modulated proton therapy (IMPT), we aim to deliver the prescribed dose to the target yet minimize the dose to adjacent healthy tissue. Mixed‐integer programming (MIP) has been applied in radiation therapy to generate treatment plans. However, MIP has not been used effectively for IMPT treatment planning with dose‐volume constraints. In this study, we incorporated dose‐volume constraints in an MIP model to generate treatment plans for IMPT.MethodsWe created a new MIP model for IMPT with dose volume constraints. Two groups of IMPT treatment plans were generated for each of three patients by using MIP models for a total of six plans: one plan was derived with the Limited‐memory Broyden–Fletcher–Goldfarb–Shanno (L‐BFGS) method while the other plan was derived with our MIP model with dose‐volume constraints. We then compared these two plans by dose‐volume histogram (DVH) indices to evaluate the performance of the new MIP model with dose‐volume constraints. In addition, we developed a model to more efficiently find the best balance between tumor coverage and normal tissue protection.ResultsThe MIP model with dose‐volume constraints generates IMPT treatment plans with comparable target dose coverage, target dose homogeneity, and the maximum dose to organs at risk (OARs) compared to treatment plans from the conventional quadratic programming method without any tedious trial‐and‐error process. Some notable reduction in the mean doses of OARs is observed.ConclusionsThe treatment plans from our MIP model with dose‐volume constraints can meet all dose‐volume constraints for OARs and targets without any tedious trial‐and‐error process. This model has the potential to automatically generate IMPT plans with consistent plan quality among different treatment planners and across institutions and better protection for important parallel OARs in an effective way.